Financial Snapshot
What does Intuitive Surgical's latest financial snapshot show?
Strong. The strongest factor is procedure-driven revenue and earnings growth, while the main concern is tariff cost pressure, lower cash after repurchases, and capital needs for manufacturing expansion.
Using FY2025 and the latest comparable quarter at March 31, 2026, this verdict combines growth, profitability, cash generation, balance-sheet capacity, and capital efficiency. For background on the business model, see Intuitive Surgical, Inc. (ISRG): History, Ownership, Mission, How It Works & Makes Money.
Operating income reached $295B for December 31, 2025, up from $235B in 2024, and Q1 2026 operating income was $85530M with diluted EPS of $228 versus $192 in Q1 2025, so the first metric to analyze more deeply is free cash flow.
Recurring Quality
Is Intuitive Surgical’s revenue growth turning into durable earnings?
Strong. The clearest confirmation is that operating income and diluted EPS both improved alongside revenue, while the large Instruments And Accessories base points to recurring demand. The main divergence is that revenue still depends on procedure growth and hospital capital spending for system placements.
Intuitive Surgical’s growth looks more like quality growth than one-time expansion, because revenue is tied to procedure activity and a growing installed base rather than a single large sale. For background on the business model, see Intuitive Surgical, Inc. (ISRG): History, Ownership, Mission, How It Works & Makes Money. Investors compare revenue durability with operating income, net income, and EPS across the same annual periods to see whether growth is converting into real earnings power.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $1006B, 2100% year-over-year growth, FY2025 Annual Total Revenue | $835B, 2024 Annual Total Revenue | Unclear; supported by procedure growth, system placements, and recurring usage | Recurring instruments and accessories revenue suggests repeatable demand |
| Operating Income | $295B, 2500% increase, FY2025 Annual Operating Income | $235B, 2024 Annual Operating Income | Operating income grew faster than revenue | Operating leverage confirms stronger earnings quality |
| Net Income | $822M, Q1 2026 GAAP Net Income | Not supplied for the comparable period | Supported by higher system placements and procedure volumes | Final earnings confirm that growth is reaching the bottom line |
| Diluted EPS | $228 per diluted share, Q1 2026 | $192 per diluted share, Q1 2025 | Shareholders received higher per-share earnings | Per-share growth matched business growth direction |
How durable is Intuitive Surgical’s revenue?
Durability looks strong because procedure volume feeds recurring instruments and accessories demand, while the installed base keeps expanding. The biggest limitation is concentration in procedure growth and hospital capital budgets for new systems.
- Demand Quality: Procedures are recurring and visible through the installed base, but system demand can still move with hospital spending.
- Pricing and Volume: Volume is clear from procedure growth; pricing and mix split were not supplied.
- Diversification: Instruments And Accessories were $602B and about 6000% of total revenue, so the model is concentrated in recurring surgical usage.
That mix matters because recurring procedure pull-through is usually easier to convert into cash than one-off equipment sales.
Cash Quality
Are Intuitive Surgical's profits supported by cash flow?
Yes, cash flow looks stronger than reported earnings in Q1 2026, with 217% operating cash flow growth and 1077% free cash flow growth. Gross profit stayed large, but tariff-related cost pressure still needs monitoring, so cash conversion appears supportive even as near-term margins face some strain.
Q1 2026 showed strong dollar profitability, with $277B revenue, $183B gross profit, $85530M operating income, and $82150M net income. Gross margin, operating margin, and net margin percentages were not supplied, so the cleaner read is that reported earnings were solid while operating cash flow, capital spending, and free cash flow need to be watched separately.
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | Q1 2026: not supplied | Prior compatible period: not supplied | Tariff impact was $63M in 2025 from increased cost of revenues, and management flagged a 17 percentage point gross margin headwind from trade barriers. | Product economics are still under pressure from input-cost and trade effects. |
| Operating Margin | Q1 2026: not supplied | Prior compatible period: not supplied | Operating expenses were $97520M, including $36190M in research and development and $61330M in selling, general and administrative expenses. | Scale is being offset by heavy investment in innovation and commercial support. |
| Net Margin | Q1 2026: not supplied | Prior compatible period: not supplied | Net income was $82150M, but margin percentages were not provided. | Final profitability is positive, but the margin trend cannot be confirmed from the supplied data. |
| Operating Cash Flow | Q1 2026: 217% growth | Previous period: not supplied | Cash flow improved sharply, but the supplied data does not give the dollar amount or working-capital bridge. | Accounting earnings appear to be converting into stronger cash generation. |
| Free Cash Flow | Q1 2026: 1077% growth | Previous period: not supplied | Growth capital expenditure rose 3643%, tied to manufacturing expansion in North America and Europe. | Reinvestment may pressure near-term cash conversion, but it supports future system supply. |
What most affects Intuitive Surgical's cash conversion?
The biggest driver is heavy reinvestment, especially 3643% growth in capital expenditure for manufacturing expansion, even though operating cash flow and free cash flow both grew sharply.
- Main Driver: Manufacturing expansion in North America and Europe looks structural, not temporary, because it is meant to support system supply.
- Evidence Gap: The supplied data does not show the exact operating cash flow or free cash flow dollar amounts.
- Metric to Monitor: Follow free cash flow growth versus capex and net income, plus tariff-related gross margin pressure.
If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help you organize the research into clear arguments. For deeper academic or investment research, a DCF valuation model or company financial analysis template can help connect Intuitive Surgical's strategy with revenue, margins, cash flow, and valuation assumptions. For company background, see Intuitive Surgical, Inc. (ISRG): History, Ownership, Mission, How It Works & Makes Money.
Balance Sheet Strength
Does Intuitive Surgical, Inc. have a balance sheet and liquidity base that can support its obligations and investment needs?
Strong. Intuitive Surgical, Inc. has the main protection of no apparent debt burden in the latest supplied data and strong interest income, while the main financing concern is lower cash after share repurchases.
Cash alone is not enough, so the better test is how working capital, asset quality, debt service, solvency, liquidity, and refinancing fit together. Based on the supplied latest data, Intuitive Surgical, Inc. shows resilience, but investors should still track whether buybacks, manufacturing expansion, R&D, and Southern Europe distribution integration keep using cash faster than it is replenished.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | $204B cash and cash equivalents at 2025-12-31; $337B cash and cash equivalents at 2026-03-31; no supplied current ratio or working capital balance. | Strong | Near-term obligations look supportable, but the cash decline after repurchases should be watched. |
| Total and Net Debt | $000 total debt at 2025-12-31; no total debt shown in the latest enterprise value data. | Strong | Very low leverage gives Intuitive Surgical, Inc. flexibility for operations and investment. |
| Debt Service and Refinancing | $000 interest expense in Q1 2026; $8510M net interest income; $8510M interest income; expected 2026 other income of $315M to $335M, mainly interest income. | Strong | No apparent refinancing stress is visible from the supplied debt and interest data. |
| Asset Quality | No supplied receivables, inventory, goodwill, intangibles, or impairment figures. | Mixed | Asset risk cannot be fully tested here, so investors should rely on future disclosures. |
| Liabilities and Equity | No supplied latest verified total liabilities or shareholders' equity. | Mixed | The capital base looks supported by cash generation, but the book balance cannot be fully checked. |
Which balance-sheet risk matters most for Intuitive Surgical, Inc.?
The main risk to monitor is cash use from buybacks and growth spending, not leverage. With no apparent debt pressure in the supplied data, liquidity discipline is the key watch item.
- Current Exposure: Cash and cash equivalents fell from $204B to $337B in the supplied periods, while total debt was $000.
- Protection: Strong interest income of $8510M and expected 2026 other income of $315M to $335M support liquidity.
- Warning Signal: Monitor whether repurchases, manufacturing expansion, R&D, and Southern Europe integration keep reducing cash faster than operations replenish it.
If you’re using this topic for a paper or case study, a structured Intuitive Surgical, Inc. (ISRG): History, Ownership, Mission, How It Works & Makes Money, SWOT Analysis, PESTLE Analysis, or debt capacity worksheet can help organize the evidence clearly.
Capital Efficiency
How efficiently is Intuitive Surgical, Inc. reinvesting for growth?
Capital efficiency looks Mixed, but still constructive. No verified ROIC, ROE, or ROA values are supplied here, yet internal cash appears broadly sufficient for reinvestment because growth is being funded mainly from operating profit, interest income, cash resources, and buyback flexibility rather than heavy leverage.
Return quality has to be read alongside leverage, asset intensity, capital expenditure, working capital, and any outside funding needs. For Intuitive Surgical, Inc., the reinvestment story is tied to manufacturing expansion, product upgrades, and installed-base support. See Intuitive Surgical, Inc. (ISRG): History, Ownership, Mission, How It Works & Makes Money for the business model context.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | No verified ratio value is supplied for ROIC. | Recent reinvestment is supported by operating scale, product launches, and expansion, but the exact return metric is unavailable. | Investors cannot confirm whether invested capital is creating operating value from the supplied data alone. |
| ROE and ROA | No verified ROE or ROA values are supplied. | Heavy leverage is not shown here, so ROE strength cannot be assumed from debt; ROA would depend on asset efficiency across the installed base. | Shareholder return quality and asset efficiency remain unproven without ratio data, even with a strong business model. |
| Maintenance and Growth Investment | Q1 2026 Research And Development Expenses were $36190M, with Rdexpense Growth of 255% at 2026-03-31. Q1 2026 Growth Capital Expenditure was 3643%. | The scale of R&D and growth capex points to heavier investment intensity, while manufacturing expansion in North America and Europe supports demand for Ion and da Vinci systems. | Capital is being pushed into product capability, capacity, and customer support, which should help growth if returns keep up. |
| Internal Funding Capacity | Growth funding appears to come from operating profit, interest income, cash resources, and buyback flexibility. Share repurchases of 23M Shares at total cost of $11B and the $50B authorization support capital return flexibility. Weighted Average Shares Diluted Growth was -017% at 2026-03-31. | The mix suggests internal funding is doing most of the work, with less reliance on balance-sheet leverage. The installed base of 1,041 Systems for Ion and 11,395 Systems for da Vinci also requires service, training, instruments, and software support. | Internal funding reduces dilution pressure and preserves flexibility, but returns can weaken if investment outruns cash generation. |
Are Intuitive Surgical, Inc.'s returns on capital sustainable?
Probably, because product leadership, installed-base scale, and manufacturing expansion support durability. The main risk is that sustained R&D and capacity spending could outpace internal cash generation if procedure growth slows.
- Operating Source: Strong product mix, da Vinci 5 full launch, regional clearances, follow-on feature releases, and 100+ updates support pricing and asset efficiency.
- Funding Requirement: The largest verified capital need is growth capex plus R&D tied to manufacturing expansion and product development.
- Durability Test: Returns would look weaker if cash reserves fall while R&D intensity and capital expenditure stay elevated without matching procedure growth.
Financial Resilience
How resilient is Intuitive Surgical, and which warning signs matter most?
Mixed. The main buffer is recurring procedure demand and the installed base that supports instrument and accessory revenue. The most important verified warning sign is tariff and supply-chain cost pressure, including the 2025 Tariff Impact of $63M and the Gross Margin Headwind of 17 percentage point forecast from trade barriers.
Intuitive Surgical can still protect liquidity and core investment because demand is partly recurring, but resilience is not unlimited if tariffs, hospital budgets, or procedure timing weaken. The company also faces policy and reimbursement sensitivity, so the link Mission Statement, Vision, & Core Values (2026) of Intuitive Surgical, Inc. (ISRG) helps explain why scale, adoption, and execution matter to the business model.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Tariffs and supply-chain costs can squeeze operating leverage, reduce earnings, and weaken cash flow and debt capacity if gross margin stays under pressure. | Recurring procedure demand and manufacturing expansion can support scale, while cost absorption improves if volumes stay strong. | Watch for gross margin erosion, weaker earnings leverage, or a larger tariff burden than the 2025 Tariff Impact of $63M. |
| Working-Capital or Investment Pressure | Higher capex, inventory, or supply-chain rework can absorb cash and reduce flexibility for R&D and expansion. | Internal funding from procedure-driven revenue and recurring instruments and accessories revenue helps support investment. | Watch for slower operating cash flow or faster asset growth without matching procedure volume. |
| Interest or Refinancing Pressure | Rising rates or refinancing stress would matter if cash flow weakened, because it would reduce flexibility for strategic spending. | Recurring cash generation provides a cushion, and no direct refinancing stress was supplied. | Watch for tighter liquidity, weaker free cash flow, or any maturity pressure if funding conditions worsen. |
Which financial warning signs should investors monitor at Intuitive Surgical?
The top signals are tariff-driven margin pressure, softer procedure growth tied to hospital and reimbursement conditions, and China volume uncertainty. Tariffs are the clearest confirmed pressure; the others are future risks to monitor through procedure growth, capital spending, and regional demand.
Tariff-driven gross margin pressure
The 2025 Tariff Impact of $63M and the Gross Margin Headwind of 17 percentage point point to hardware cost exposure. Manufacturing expansion and supply-chain adjustments help, but the next metric is gross margin trend.
Procedure demand and hospital budget sensitivity
ACA subsidy risk and European capital pressure can slow elective procedures and delay purchases. Diversification into general surgery in the United States and non-urology procedures internationally helps, so monitor procedure growth and system demand.
China tender volume uncertainty
China adds regional growth risk because tender volumes can shift with macro conditions and competition. The global procedure base and recurring instruments and accessories revenue soften the impact, so watch China sales and procedure visibility.
Strong Balance Sheet
What does Intuitive Surgical's financial health mean for investors?
Overall, Intuitive Surgical is rated Strong. The strongest factor is procedure-driven revenue and earnings growth, and the weakest is tariff and regional demand pressure. The key investment condition is cash discipline while funding da Vinci 5, Ion, manufacturing, and buybacks. For business context, see Intuitive Surgical, Inc. (ISRG): History, Ownership, Mission, How It Works & Makes Money.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Strong | FY2025 revenue of $1006B, 2100% year-over-year growth, Q1 Revenue of $277B, 2300% year-over-year growth, and Q1 EPS Diluted of $228 versus $192 show durable top-line and per-share momentum. |
| Profitability and Cash | Strong | FY2025 Operating Income of $295B and Q1 2026 Operating Income of $85530M support strong earnings power, though tariffs and reinvestment needs can pressure cash conversion. |
| Balance Sheet and Liquidity | Strong | Minus Cash And Cash Equivalents of $204B, Add Total Debt of $000, and Interest Expense of $000 point to low leverage and limited debt service risk. |
| Capital Efficiency | Mixed | Internal funding, R&D, manufacturing expansion, and buybacks support growth, but verified ROIC, ROE, and ROA ratios are not supplied, so return quality is harder to judge. |
| Financial Resilience | Mixed | Recurring procedure demand and installed base scale help, but tariff, ACA subsidy, China tender, and European capital spending risks can affect demand and margins. |
- What Supports the Thesis: Strong procedure-driven growth plus conservative leverage and recurring demand support durable cash generation.
- What Challenges the Thesis: Tariffs, regional demand pressure, and heavy reinvestment needs could slow margin and cash-flow gains.
- What to Monitor: Q1 Procedure Growth or updated procedure guidance, Free Cash Flow Growth, and Minus Cash And Cash Equivalents.
Forecasts should test whether growth, cash flow, and reinvestment needs stay aligned across base, bull, and bear scenarios before any valuation work.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
How much do tariffs pressure Intuitive Surgical's gross margin?
Management-linked risk data includes a Gross Margin Headwind of 17 percentage point from trade barriers and a 2025 Tariff Impact of $63M Investors should watch whether pricing, mix, manufacturing expansion, or supply-chain changes offset cost pressure
Does Intuitive Surgical generate enough cash for buybacks?
Q1 2026 Free Cash Flow Growth was 1077%, and Q1 Share Repurchases were 23M Shares at total cost of $11B The $50B repurchase authorization adds flexibility, but lower cash after buybacks should be monitored
Is Intuitive Surgical using debt to fund expansion?
The latest enterprise value data showed Add Total Debt of $000 at 2026-03-31, with Interest Expense of $000 in Q1 2026 That suggests expansion is not being funded through heavy reported debt in the supplied data
What does procedure growth mean for ISRG's resilience?
Procedure growth supports recurring instruments and accessories demand, which made up approximately 6000% of FY2025 revenue Q1 Procedure Growth was 1700%, helping offset some cyclicality in capital equipment placements and regional hospital spending pressure
Which liquidity signals matter most for Intuitive Surgical?
Investors should track Minus Cash And Cash Equivalents of $204B, Add Total Debt of $000, Interest Expense of $000, and expected 2026 Other Income of $315M to $335M These indicate liquidity capacity and cash balance sensitivity after repurchases